Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Core Viewpoint - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel biotherapeutics for challenging diseases, including cancer, inflammation, and autoimmune diseases, with an upcoming financial results announcement and corporate update scheduled for May 8, 2025 [1][2]. Company Overview - Zymeworks is dedicated to the discovery, development, and commercialization of multifunctional biotherapeutics, aiming to significantly impact the lives of patients with difficult-to-treat conditions [3]. - The company has developed zanidatamab, a HER2-targeted bispecific antibody utilizing proprietary Azymetric™ technology, and has secured exclusive development and commercialization agreements with BeiGene and Jazz Pharmaceuticals [3]. - Ziihera® (zanidatamab-hrii) has received accelerated approval from the U.S. FDA for treating adults with previously-treated, unresectable or metastatic HER2-positive second-line biliary tract cancer, marking it as the first dual HER2-targeted bispecific antibody approved for this indication in the U.S. [3]. - Zanidatamab is under regulatory review in the EU and China and is being evaluated in global clinical trials for various HER2-expressing cancers [3]. - Zymeworks is advancing a robust pipeline of product candidates, with ongoing Phase 1 studies for ZW171 and ZW191, and plans for an investigational new drug application for ZW251 in mid-2025 [3]. Upcoming Events - The company will report its first quarter 2025 financial results after market close on May 8, 2025, followed by a conference call and webcast at 4:30 pm Eastern Time [1].